Skip to main content.
kumc.edu
Home

Andrew K. Godwin, Ph.D.

Andrew Godwin
Professor, Pathology and Laboratory Medicine

Professor, Microbiology, Molecular Genetics and Immunology

Professor, Cancer Biology

agodwin@kumc.edu

Professional Background

Dr. Godwin is a leader in the field of translational research and precision medicine, and his laboratories at KUMC continue to focus on various aspects of both basic and translational research. He is a NCI funded investigator (continuously since 1993) and a highly published (>380 manuscripts and scholarly review articles) and cited (>33,500; h-index of 97) scientist. Dr. Godwin is internationally recognized for his molecular biology/genetic studies of cancers including, sarcoma, breast and ovarian, and his efforts to help bridge the gap between basic and clinical science in order to improve patient care. Through the CMOL and BDL, Godwin's group continues to support the development and advancement of rationally designed therapeutic strategies to improve the options for patient treated at the KU Cancer Center.

Education and Training
  • BS, Cellular Biology, Univ. of Kansas
  • PhD, Molecular Biology, Univ. of Pennsylvania
  • Other, Molecular mechanisms of cisplatin resistance in ovarian cancer cells, Fox Chase Cancer Center, Division of Medical Sciences, Philadelphia, PA
  • Other, Spontaneous transformation of ovarian surface epithelial cells and molecular mechanisms of drug resistance in human ovarian cancer cells, Fox Chase Cancer Center, Division of Medical Sciences, Philadelphia, PA

Research

Overview

Dr. Godwin is a member of multiple disease-working groups for The Cancer Genome Atlas (TCGA), the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA), an international group studying large cohorts of BRCA1/2 mutation carriers for genetic modifiers of breast cancer risk, the Early Detection Research Network (EDRN) for >12 years, and the Early Therapeutics and Rare Cancers Committee and of the Breast Translational Medicine Working Group of the Southwest Oncology Group (SWOG). His research programs continue to focus on various aspects of both basic and translational research, with an emphasis on early detection of cancer, predictive and prognostic biomarkers, liquid biopsies based on extracellular vesicles (e.g., exosomes), molecular therapeutics, companion diagnostics, clinical trials, and biosample ascertainment.